Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mirikizumab (LY3074828), a humanized IgG4 monoclonal antibody, specifically targets the p19 subunit of interleukin 23. It is currently under research for its potential application in treating ulcerative colitis [1].
説明 | Mirikizumab (LY3074828), a humanized IgG4 monoclonal antibody, specifically targets the p19 subunit of interleukin 23. It is currently under research for its potential application in treating ulcerative colitis [1]. |
分子量 | N/A |
CAS No. | 1884201-71-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mirikizumab 1884201-71-1 Inhibitor inhibitor inhibit